Seeking Alpha

FDA gets tougher on hydrocodone in effort to battle abuse

  • The FDA is set to reclassify hydrocodone-based painkillers as Schedule II substances (up from Schedule III) to reflect their potential for abuse.
  • What it means (practically speaking): Refills would be limited to a 90-day supply as opposed to 180 days.
  • Companies that make either brand name or generic versions: AbbVie (ABBV), Actavis (ACT), Teva (TEVA), Mallinckrodt (MNK).
From other sites
Comments (2)
  • Micro_Cap_Maven
    , contributor
    Comments (107) | Send Message
     
    Considering that MNK has the only abuse-resistant format of hydrocodone (MNK-795) in the pipeline and set to launch in 2014, this certainly makes the launch far more timely.
    25 Oct 2013, 09:30 AM Reply Like
  • msapp
    , contributor
    Comments (377) | Send Message
     
    ZLCS's Z160 - N type calcium channel blocker for pain in phase 11 for PHN and LSR pain data is due in 4Q 2013. This is non addictive, does not cause sensory symptoms, and works on the level of morphine and gabapentin. This could change the way pain is treated.
    29 Oct 2013, 12:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs